Note on Forward-looking Statements

Transcription

1

2 Note on Forward-looking Statements These presentations contain forward-looking statements as defined in the Private Securities Litigation Reform Act of These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents obtained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.

3 Note on Forward-looking Statements A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company s Annual Report on Form 10-K for the fiscal year ended December 28, Copies of this Form 10-K, as well as subsequent filings, are available online at or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments.

4 Pharmaceutical R&D Paul Stoffels, M.D. Global Head, Research & Development Pharmaceuticals

5 Fueling Growth Through Innovation Overview Pipeline highlights Managing for the long-term R&D strategy and operating model Well positioned for the future

6 Pharmaceutical Research & Development Leadership in pharmaceutical research and development Innovative platforms and technologies Global operations with end-to-end capabilities Outcomes-based development Robust pipeline

7 Pipeline Productivity on Track Key Pharmaceutical R&D results: 2008 to date Record submissions and approvals 6 NMEs approved in major markets Several regulatory filings in the U.S. and EU Outstanding late development progress 5 compounds advanced to full development Portfolio expansion through Licensing and acquisitions Establishing collaborations Creating new partnerships in emerging regions

8 NME Approvals and Filings: 2008 to Date Approvals INTELENCE (etravirine) HIV (U.S., EU) DORIBAX (doripenem) ciai, cuti, nosocomial pneumonia (EU) NUCYNTA (tapentadol) Acute pain (U.S.*) STELARA (ustekinumab) Psoriasis (EU) PRILIGY (dapoxetine) Premature ejaculation (EU) SIMPONI (golimumab) Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis (U.S.) *PDUFA approval, DEA scheduling effective June 2009 **Approved in Canada, Ukraine and Switzerland Registration ZEFTERA (ceftobiprole) Complicated skin (U.S.**) ZEVTERA (ceftobiprole) Complicated skin (EU) INVEGA SUSTENNA (paliperidone palmitate) Schizophrenia (U.S.) STELARA (ustekinumab) Psoriasis (U.S.) SIMPONI (golimumab) Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis (EU) Rivaroxaban VTE prophylaxis (U.S.) COMFYDE (carisbamate) Epilepsy (U.S.) YONDELIS (trabectedin) Ovarian cancer (U.S.)

9 Major LEs: Approvals and Filings 2008 to Date U.S. EU Japan Approvals CONCERTA Adult ADHD DOXIL AIDS-Kaposi Sarcoma PREZISTA Early experienced and naïve RISPERDAL CONSTA Deltoid RISPERDAL CONSTA Monotherapy and adjunctive treatment for bipolar maintenance Filings DOXIL Metastatic breast cancer INVEGA Schizoaffective disorder STELARA Psoriasis (pre-filled syringe) Approvals PREZISTA Early experienced and naïve REMICADE Ulcerative colitis colectomy avoidance VELCADE 1 st line multiple myeloma Filings RISPERDAL CONSTA Bipolar maintenance and deltoid STELARA Psoriasis (pre-filled syringe) Approvals DUROTEP Matrix cancer pain PREZISTA Early experienced and naïve RISPERDAL CONSTA Schizophrenia Filings DTRANS Fentanyl 1 day patch cancer pain

10 A Robust and Balanced Pipeline Our pipeline encompasses Differentiated therapies, addressing major unmet medical needs Addressing needs in significant markets global and/or large regional markets Diversified portfolio, including NMEs and major line extensions, small and large molecules Several pipelines within products Targeted therapies with expanding indications

11 Pipeline in a Product Example Pipeline in a product approach began with REMICADE >1 million patients treated Using similar approach in SIMPONI STELARA Rivaroxaban 15 indications

12 Rivaroxaban: Pipeline in a Product Example Pipeline in a product approach began with REMICADE Similar approach in: SIMPONI STELARA Rivaroxaban Venous thromboembolism (VTE) prevention VTE treatment Stroke prevention in atrial fibrillation VTE prevention in medically ill Secondary prevention of CV events in acute coronary syndrome

13 Managing for the Long-term Innovation Sustained R&D productivity Evolving our R&D strategy Operating model

14 Changing Landscape of Health Care Pricing, Patents, Competition Higher Threshold for Innovation Challenges Regulatory Hurdles Payors Higher Cost and Risk

15 Changing Landscape of Health Care Science and Technology Open Innovation Opportunities Convergence and Personalized Medicine High Demand for New Treatments Globalization

16 Changing Landscape Calls for R&D Paradigm Shift Developing Products Opportunistic Internally focused Bricks and mortar based research models Addressing regulatory authorities requirements Proving safety and efficacy High-cost and incremental innovations Internally financed OLD PARADIGM NEW PARADIGM Developing Solutions Strategic Open innovation Flexible models Meeting payor and patient needs Outcomes-based Affordable and value-added Risk-sharing partnerships

17 Drivers for Future Success in the Industry Matching medical need with the best science and operational excellence Therapeutic Area Focus Open Innovation Outstanding Talent Unmet Medical Needs Broad Based Expertise & Global Reach Outcomes Based Development

18 Drivers for Future Success in the Industry Matching medical need with the best science and operational excellence Therapeutic Area Focus Open Innovation Focus on addressing high medical needs, markets Efficient resource utilization Outstanding Talent Unmet Medical Needs Outcomes Based Development Broad Based Expertise & Global Reach

19 Drivers for Future Success in the Industry Matching medical need with the best science and operational excellence Therapeutic Area Focus Open Innovation Outstanding Talent Unmet Medical Needs Increased innovation, access to best science Internal innovation, Licensing & Acquisitions, external science Outcomes Based Development Broad Based Expertise & Global Reach

20 Drivers for Future Success in the Industry Matching medical need with the best science and operational excellence Therapeutic Area Focus Open Innovation Outstanding Talent Unmet Medical Needs Broad Based Expertise & Global Reach Outcomes Based Development Meeting patient and payor requirements

21 Drivers for Future Success in the Industry Matching medical need with the best science and operational excellence Therapeutic Area Focus Open Innovation Outstanding Talent Increased efficiency, cost effectiveness and flexibility Innovation, novel resources and markets R&D to commercial follow through Unmet Medical Needs Broad Based Expertise & Global Reach Outcomes Based Development

22 Drivers for Future Success in the Industry Matching medical need with the best science and operational excellence Expertise Therapeutic Area Focus Therapeutic area leadership Entrepreneurial culture Open Innovation Outstanding Talent Unmet Medical Needs Outcomes Based Development Broad Based Expertise & Global Reach

23 Drivers for Future Success in the Industry Matching medical need with the best science and operational excellence Therapeutic Area Focus Open Innovation Outstanding Talent Unmet Medical Needs Broad Based Expertise & Global Reach Outcomes Based Development

24 Our Strategy for Pharmaceutical R&D Five key elements Therapeutic Area Focus Focus on end-to-end, research to market approach in five therapeutic areas Open Innovation Combine internal innovation with external innovation Outcomes Based Development Embed customer, physician, and payor insights Broad Based Expertise & Global Reach Leverage broad based expertise and global capabilities Outstanding Talent Outstanding talent and exceptional expertise

25 Five Therapeutic Area Focused End-to-End Units Therapeutic Area Focus Therapeutic Areas Neuroscience CV and Metabolism Infectious Diseases Immunology Oncology End-to-End Organization Discovery Early Development Late Development Lifecycle Management

26 Disease Area Focus within Therapeutic Areas Today and in the future Therapeutic Area Focus Neuroscience Schizophrenia, epilepsy, pain, cognition and dementia Cardiovascular and metabolism Heart disease, diabetes and obesity Infectious diseases HIV long-acting formulations, HCV, multi-drug resistance in antibacterials and antivirals Immunology Small and large molecules, and pulmonary diseases Oncology Tumor microenvironment

27 Accessing the Best Science Open Innovation LICENSING AND ACQUISITIONS Neuroscience CV and Metabolism INTERNAL RESEARCH Discovery OPEN INNOVATION Early Development Late Development New Drug Application Infectious Diseases Immunology EXTERNAL INNOVATION Academia Biotech Pharma Consortia Oncology

28 Accessing the Best Science Open innovation strategy example Open Innovation Tibotec Acquisition PREZISTA HIV PI Tibotec Acquisition INTELENCE HIV NNRTI Vertex Collaboration Telaprevir HCV PI HIV-HCV Portfolio Internal Innovation TMC 278 HIV Internal Innovation TMC 207 MDR-TB Collaboration with Medivir TMC 435 HCV PI Collaboration with Medivir HCV NI, NNI

29 Partnering for Innovation Open Innovation Academic Tianjin Medical University Cancer Hospital, China Vanderbilt University (U.S.) Biotech Molecular Partners (EU) Catalyst Biosciences (U.S.) Advinus (India) Government Medical Research Council (UK) National Cancer Institute Consortia Biomarkers, serious adverse events and RNAi

30 Outcomes Based Drug Development Outcomes Based Drug Development Measuring outcomes that matter to patients Embedding real world insights into drug development Clinical trials with hard endpoints Standard of care as comparison in many trials Large clinical programs Rivaroxaban Global focus

31 Global, Leveraged Platforms and Development Operations Broad Based Expertise & Global Reach Decentralized Therapeutic Areas Neuroscience CV and Metabolism Infectious Diseases Immunology Oncology Biotechnology, Small molecules, Biomarkers and Drug-Diagnostics platforms Global Development Operations Leveraged Platforms and Expertise

32 Leveraging Biotechnology Capabilities Broad Based Expertise & Global Reach Building on leadership in biotechnology Core strengths and infrastructure in discovery, development and manufacturing Traditional areas of biotech focus: oncology, immunology and hematology Leveraging biotech capabilities across all therapeutic areas Opportunity to benefit more patients Anti-NGF compound

33 Leveraging Small Molecule Chemistry and Pharmaceutical R&D Capabilities Broad Based Expertise & Global Reach Global preclinical development ADME* (incl. pharmacokinetics) Toxicology Preclinical and clinical pharmacology Global chemical pharmaceutical development Active Pharmaceutical Ingredient (API) capability world wide Broad form and formulation expertise and capabilities Novel enabling technologies * ADME Absorption, Distribution, Metabolism, Excretion

34 Global Operations and Reach Efficient and versatile R&D organization with the ability to develop, register and launch drugs globally Broad Based Expertise & Global Reach R&D centers in West Coast U.S., East Coast U.S., EU and Asia, including Japan Clinical trial operations in 55 countries Manage more than 6,000 study sites worldwide About 50% of new subjects from emerging regions Approximately 500 clinical studies managed in 2008 Significant data management capabilities in Asia Global ChemPharm capabilities, including India and China

35 Leveraging Biomarker and Pharmacogenomic Capabilities Biomarkers and pharmacogenomics Large clinical databases Psychiatry, oncology, virology, immunology, and metabolics Markers for efficacy and side effects Broad Based Expertise & Global Reach Routinely used in all aspects of our drug development Connect In Vitro, pre-clinical and clinical knowledge Retrospective and prognostic

36 Leveraging Drugs and Diagnostics Broad Based Expertise & Global Reach Unique combination of drugs and diagnostics know-how at Johnson & Johnson HIV/AIDS Use of viral load as surrogate marker Combining diagnostics and therapeutics Faster development, approval and reimbursement Oncology Ability to choose appropriate treatments Neuroscience Potential for more effective treatments

37 Globalization Building capabilities in Asia Fast growing economies Changing landscape of disease Unprecedented demand Chemical pharmaceutical facility launched in Mumbai Expanding network in China Expanding clinical development in Japan Robust pipeline

38 Potential Filings in India, China and Japan: India China Japan YONDELIS DACOGEN YONDELIS COMFYDE RAZADYNE /REMINYL VELCADE VELCADE SIMPONI VELCADE TMC 278 REMICADE TMC 278 ZEFTERA TMC 278 INVEGA SUSTENNA TMC 207 DTRANS Rivaroxaban STELARA TMC 207 PRILIGY STELARA TOPAMAX ZEFTERA INVEGA SUSTENNA Telaprevir RISPERDAL CONSTA CNTO 328 PREZISTA DACOGEN REMICADE CNTO 328 SIMPONI NUCYNTA STELARA CNTO 136 PREZISTA SGLT2 ZEFTERA TMC 435 PREZISTA TMC 435 COMFYDE TMC 435 SIMPONI SGLT2 ULTRACET PRILIGY INVEGA

39 A Robust and Balanced Pipeline Our pipeline encompasses Differentiated therapies, addressing major unmet medical needs Addressing needs in significant markets global and/or large regional markets Diversified portfolio, including NMEs and major line extensions, small and large molecules Several pipelines within products Targeted therapies with expanding indications

40 Potential NME Filings: Planned Filings: Planned Filings: Telaprevir (EU) HCV TMC 278 HIV DACOGEN (EU) AML Histamine H3 Antagonist Adult ADHD Anti-NGF Pain Canagliflozin (SGLT-2) Type 2 diabetes Gut-specific MTP inhibitor Obesity TMC 207 MDR-TB TMC 435 HCV CNTO 328 Castleman s disease/oncology CNTO 136 Rheumatoid arthritis

41 Potential NME Approvals and Filings: Approvals Registration Planned Filings INTELENCE (etravirine) HIV (U.S., EU) DORIBAX (doripenem for injection) ciai, cuti, NP (EU) NUCYNTA (tapentadol) Acute pain (U.S.) STELARA (ustekinumab) Psoriasis (EU) PRILIGY (dapoxetine) Premature ejaculation (EU) SIMPONI (golimumab) RA, AS, PsA (U.S.) ZEFTERA (ceftobiprole) Complicated skin (U.S.*) ZEVTERA (ceftobiprole) Complicated skin (EU) INVEGA SUSTENNA (paliperidone palmitate) Schizophrenia (U.S.) STELARA (ustekinumab) Psoriasis (U.S.) SIMPONI (golimumab) RA, AS, PsA (SC, PFS) (EU) Rivaroxaban VTE prophylaxis and treatment (U.S.) COMFYDE (carisbamate) Epilepsy (U.S.) YONDELIS (trabectedin) Ovarian cancer (U.S.) Telaprevir (EU), HCV TMC 278, HIV DACOGEN (EU), AML H3 Antagonist, Adult ADHD Anti-NGF, Pain Canagliflozin (SGLT-2), Type 2 diabetes Gut-specific MTP inhibitor, Obesity TMC 207, MDR-TB TMC 435, HCV CNTO 328, Castleman s disease/oncology CNTO 136, Rheumatoid arthritis *Approved in Canada, Ukraine and Switzerland

42 Selected Potential Additional Filings by 2013 (LEs) Product Indication Product Indication REMICADE SIMPONI STELARA Rivaroxaban PROCRIT Pediatric ulcerative colitis Ulcerative colitis (Japan) Structural damage (RA, PsA) major clinical response & physical functions Rheumatoid arthritis (IV) Ulcerative colitis Psoriasis (Japan) Psoriatic arthritis Crohn s disease Stroke prevention in Afib VTE treatment VTE prevention in medically ill Secondary prevention in ACS Chronic renal function extended dosing Myelodysplastic syndrome NUCYNTA INVEGA CONCERTA DTRANS Moderate-to-severe chronic pain (ER) Chronic pain (TRF) Diabetic peripheral neuropathy Bipolar recurrence prevention Schizoaffective disorder (EU) Pediatric exclusivity Adult ADHD OROS (EU) Fentanyl 1 day patch non-cancer pain (Japan) VELCADE Non Hodgkin s lymphoma Relapsed refractory NHL First line Mantle Cell lymphoma Subcutaneous formulation ULTRACET Pain (Japan)

43

44 Our Aspirations

45